104 related articles for article (PubMed ID: 38948581)
1. Safety monitoring of precautionary third dose of COVID-19 vaccines in a district in Northern India.
Deb T; Misra S; Kaur M; Verma N; Kairi JK; Sindhu N
J Family Med Prim Care; 2024 May; 13(5):1875-1880. PubMed ID: 38948581
[TBL] [Abstract][Full Text] [Related]
2. ADR Profile of the Covishield Vaccine Among Healthcare Workers in a Tertiary Care Teaching Hospital in India.
Deb T; Garg R; Kaur M; Beniwal A; Gupta V
Curr Drug Saf; 2022; 17(4):344-349. PubMed ID: 35049437
[TBL] [Abstract][Full Text] [Related]
3. Coverage of Coronavirus Disease-2019 (COVID-19) Booster Dose (Precautionary) in the Adult Population: An Online Survey.
Masthi Nr R; Brahmajosyula A; Khamar A; Acharya N; Bilichod LP; Kondath D
Cureus; 2022 Jul; 14(7):e26912. PubMed ID: 35983381
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
[TBL] [Abstract][Full Text] [Related]
5. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
Elife; 2023 Jan; 12():. PubMed ID: 36692910
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
[TBL] [Abstract][Full Text] [Related]
7. Acceptance of Annual Booster Doses of COVID-19 Vaccines Among Indian Healthcare Professionals: A Pan-India Cross-Sectional Survey.
Krishna E; Karthikeyan V; Ahmad S; Ranjan A; Hasan Km A; Pandey S; Kumar P; Singh CM
Cureus; 2023 Nov; 15(11):e49363. PubMed ID: 38146559
[TBL] [Abstract][Full Text] [Related]
8. Stimulated Reporting of Adverse Events Following Immunization with COVID-19 Vaccines.
Jhaj R; Chaudhary D; Shukla AK; Yadav J
Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560545
[TBL] [Abstract][Full Text] [Related]
9. A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?
El-Menyar A; Khan NA; Mekkodathil A; Rizoli S; Consunji R; Elmenyar E; Galwankar S; Al-Thani H
Medicine (Baltimore); 2022 Sep; 101(37):e30609. PubMed ID: 36123868
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
Front Immunol; 2022; 13():928501. PubMed ID: 36211366
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
[TBL] [Abstract][Full Text] [Related]
13. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
[TBL] [Abstract][Full Text] [Related]
14. [Investigation of Humoral and Cellular Immunity in TOBB ETÜ Hospital Workers After Three Doses of CoronaVac Vaccination and after One Dose of Comirnaty Vaccination Following Two Doses of CoronaVac].
Özyurda F; Ardıçoğlu Akışın Y; Mert T; Poyraz B; Özkan Y; Turan M; Göçmen JS; Yücel A; Akar N
Mikrobiyol Bul; 2022 Jul; 56(3):387-403. PubMed ID: 35960233
[TBL] [Abstract][Full Text] [Related]
15. Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
Makanut S; Wangteeraprasert A; Jitpewngam W; Ngoenkam J; Pongcharoen S
Vaccine; 2023 Jun; 41(29):4335-4340. PubMed ID: 37301707
[TBL] [Abstract][Full Text] [Related]
16. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.
Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A
Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.
Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD
JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661
[TBL] [Abstract][Full Text] [Related]
18. Safety Monitoring of COVID-19 Vaccines in Persons with Prior SARS-CoV-2 Infection: A European Multi-Country Study.
Ciccimarra F; Luxi N; Bellitto C; L'Abbate L; Raethke M; van Hunsel F; Lieber T; Mulder E; Riefolo F; Dureau-Pournin C; Farcas A; Batel Marques F; Morton K; Roy D; Sonderlichová S; Thurin NH; Villalobos F; Sturkenboom MC; Trifirò G
Vaccines (Basel); 2024 Feb; 12(3):. PubMed ID: 38543875
[TBL] [Abstract][Full Text] [Related]
19. Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.
Raethke M; van Hunsel F; Luxi N; Lieber T; Bellitto C; Mulder E; Ciccimarra F; Riefolo F; Thurin NH; Roy D; Morton K; Villalobos F; Batel Marques F; Farcas A; Sonderlichová S; Belitser S; Klungel O; Trifirò G; Sturkenboom MC
Vaccine; 2024 Apr; 42(9):2357-2369. PubMed ID: 38448322
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
